Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Entera Bio Ltd.NASDAQ: ENTX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$2.96M, compared with $11.91M a year earlier. Trailing-twelve-month net change in cash was -$8.65M.
Context
- Net change in cash amounted to 14840.5% of revenue in FY2025, up 13544.9 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$2.96M or moves back toward the trailing-twelve-month quarterly average of -$2.16M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 6.23M USD
- Year-over-year change
- +365.8%
- 4-year CAGR
- -21.4%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.23M | +365.8% |
| FY2024 | 2024-12-31 | (2.35M) | -81.6% |
| FY2023 | 2023-12-31 | (1.29M) | +89.7% |
| FY2022 | 2022-12-31 | (12.58M) | -177.2% |
| FY2021 | 2021-12-31 | 16.3M | — |
Net Change in Cash vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's LTM Mar 2026 net change in cash of $8.65M is the 6th largest of the 10 companies compared; the peer median is $78.3K.
- Its year-over-year change of -175.8% is the lowest of 9, against a peer median of +132.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.02M | -44.3% | — | 2529.6% | |
| LTM Mar 2026 | $21.64M | +229.0% | +32.2% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $18.17M | +438.4% | -6.6% | 151.6% |
| LTM Mar 2026 | $14.59M | +142.4% | -31.9% | 11.8% | |
| LTM Mar 2026 | $13.64M | -167.2% | -4.6% | — | |
| LTM Mar 2026 | $8.65M | -175.8% | — | — | |
| LTM Mar 2026 | $7.24M | +121.7% | +53.7% | 13.2% | |
| LTM Mar 2026 | $5.13M | +162.5% | — | 34.1% | |
| LTM Apr 2026 | $433K | -147.3% | -88.3% | — | |
| LTM Mar 2026 | $78.3K | — | — | — | |
| Peer median (excluding ENTX) | $78.3K | +132.0% | -5.6% | 34.1% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.19M) | (13.07M) | (8.89M) | (9.54M) | (11.44M) |
| Depreciation & Amortization | 53K | 64K | 56K | 46K | 30K |
| Deferred Income Tax | (217K) | 174K | 29K | 14K | 0 |
| Stock-Based Compensation | 1.86M | 2.25M | 1.69M | 2.56M | 2.75M |
| Change in Working Capital | 1.41M | (1.84M) | (195K) | 112K | 1.26M |
| Accounts Receivables | 72K | (63K) | 246K | (126K) | 126K |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 74K | (149K) | 66K | 49K | 316K |
| Other Working Capital | 1.34M | (1.62M) | (507K) | 189K | 815K |
| Other Non-Cash Items | 18K | (78K) | 1.69M | (5K) | 32K |
| Operating Cash Flow | (9.06M) | (12.5M) | (7.31M) | (6.82M) | (7.37M) |
| Capital Expenditures | (17K) | (47K) | (17K) | (3K) | (107K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (55K) | 0 | 0 | 0 |
| Investing Cash Flow | (17K) | (102K) | (17K) | (3K) | (107K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 21.81M | 13K | 6.62M | 3.96M | 13.71M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.58M | 0 | (580K) | 516K | 0 |
| Financing Cash Flow | 25.38M | 13K | 6.04M | 4.48M | 13.71M |
| Effect of Forex Changes | 0 | 5K | 0 | 0 | (10K) |
| Net Change in Cash | 16.3M | (12.58M) | (1.29M) | (2.35M) | 6.23M |
| Free Cash Flow | (9.08M) | (12.55M) | (7.33M) | (6.82M) | (7.48M) |
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.